Xycota Advances At-Home Brain Repair Research Alongside Free Support Platform for Veterans

2026-11-12 companies

New York, Wednesday, 11 November 2026.
Xycota Biosciences launched a privacy-first support hub while advancing clinical trials for an at-home, low-dose psilocybin treatment designed to trigger neural repair without causing hallucinations or requiring lengthy clinic visits.

Immediate Support for Trauma-Affected Communities

On Veterans Day 2026, Xycota Biosciences launched a no-cost, zero-login digital PTSD support platform (https://xycota.com/ptsd) designed explicitly for veterans, active-duty service members, first responders, and their families [1][5][9]. The platform delivers immediate crisis intervention tools, including a 60-second physiological sigh pacer, a 4-4-4-4 box breathing timer, and a 5-4-3-2-1 sensory grounding exercise—all delivered through a private browser-only interface that avoids cloud storage and account creation [1][5][9]. Users gain instant access to a confidential support matcher that connects them with vetted resources such as the 988 Veterans Crisis Line, VA Vet Centers, The Headstrong Project, and local veteran service organizations [1][5][9]. The initiative reflects a dual commitment to community support and clinical innovation, with the platform positioned as a bridge between immediate need and ongoing research into psychedelic-assisted therapies [1][5][9].

Sub-Perceptual Psilocybin Therapy Targeting Neural Repair

Concurrently, Xycota Biosciences is advancing XYCO-02, a sub-perceptual oral psilocybin formulation engineered to stimulate BDNF/TrkB neural repair pathways without inducing hallucinations or requiring prolonged in-clinic supervision [1][5][9]. The company is preparing a clinical trial application in Canada with KGK Science to evaluate the therapeutic potential of low-dose psilocybin for outpatient use, specifically targeting the brain’s synaptic repair mechanisms implicated in trauma recovery [1][5][9]. This approach is grounded in preclinical evidence, including a 2026 Neuropsychopharmacology study (Ascone et al.) co-authored by Xycota’s Chief Scientific Officer Dr. Marvin S. Hausman, which demonstrated that repeated low-dose oral psilocybin restored object-recognition memory in a genetic rat model of Fragile X syndrome via the BDNF/TrkB pathway [1][5][7][9]. While the study was conducted in rats and did not evaluate PTSD or human subjects, it provides a mechanistic rationale for exploring sub-perceptual psilocybin as a non-hallucinogenic therapeutic [1][5][7][9].

Structured Corporate Integration with BioAdaptives

The company’s strategic alignment with BioAdaptives, Inc. (OTCID: BDPT)—announced on October 29, 2026, and formalized in an 8-K filing on November 4, 2026—maintains distinct operational entities for biotech and nutraceutical development while incorporating safeguards for shareholders [1][5][9]. The agreement includes a 12-month founder lock-up period, structured limits on daily note resales, and milestone-gated research and development (R&D) funding tranches to ensure disciplined financial progression [1][5][9]. BioAdaptives’ pending acquisition of Xycota is designed to enable eligible shareholders to eventually hold shares in two separate companies, with conditional funding allocated for a proposed nutraceutical spin-off [1][5][9]. This structure underscores a commitment to long-term value creation while preserving operational autonomy for both entities [1][5][9].

Convergence of Community and Clinical Innovation

The launch of the PTSD support hub and the preparation of XYCO-02 for clinical trials represent a convergence of community-focused intervention and cutting-edge neuroscience [1][5][9]. Xycota’s leadership emphasizes the importance of accessible, stigma-free tools for trauma-affected populations, with CEO Brad Listermann stating that the company aimed to provide ‘free, private, zero-red-tape tools’ to veterans and first responders before drug candidates reach human trials [1][5][9]. Dr. Hausman further contextualized the approach, noting that ‘chronic trauma leaves a measurable physical imprint on synaptic connections, not a character flaw,’ framing the research as a pursuit of biologically informed healing [1][5][9]. As Xycota prepares its Canadian clinical trial application, the company’s dual-track strategy—combining immediate support with long-term therapeutic innovation—positions it at the intersection of urgent care and transformative medicine [1][5][9].

Sources

biotechnology BioAdaptives